Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAscendis Pharma A/S Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 5 | -$0.33 | $0.63 | $0.16 |
| Q2 2026 | 5 | $0.70 | $5.02 | $1.49 |
| Q3 2026 | 5 | $0.47 | $1.31 | $0.99 |
| Q4 2026 | 5 | -$115.09 | $26.68 | $1.40 |
| Q1 2027 | 3 | $1.71 | $1.93 | $1.81 |
| Q2 2027 | 3 | $2.13 | $2.41 | $2.26 |
| Q3 2027 | 3 | $2.31 | $2.62 | $2.45 |
| Q4 2027 | 3 | $2.87 | $3.25 | $3.04 |
Ascendis Pharma A/S Earnings Date And Information
Ascendis Pharma A/S last posted its earnings results on Thursday, August 13th, 2026. The company reported $3.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $1.58. The company had revenue of 344.90 M for the quarter and had revenue of 691.71 M for the year. Ascendis Pharma A/S has generated $-4 earnings per share over the last year ($-3.62 diluted earnings per share) and currently has a price-to-earnings ratio of 17.94. Ascendis Pharma A/S has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Ascendis Pharma A/S Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/13/2026 | Q2 2026 | $1.71 | $3.27 | 1.56 | $329.39 M | $344.90 M |
| 05/07/2026 | Q1 2026 | $0.19 | $10.37 | 10.18 | $268.82 M | $250.66 M |
| 02/11/2026 | Q4 2025 | -$0.06 | -$0.54 | -0.48 | $245.50 M | $245.18 M |
| 11/12/2025 | Q3 2025 | -$0.41 | -$1.00 | -0.59 | $213.64 M | $213.63 M |
| 08/07/2025 | Q2 2025 | -$1.42 | -$0.64 | 0.78 | $144.78 M | $158.05 M |
| 05/01/2025 | Q1 2025 | -$1.56 | -$1.58 | -0.02 | $94.81 M | $100.95 M |
| 02/12/2025 | Q4 2024 | -$1.20 | -$0.64 | 0.56 | $118.75 M | $173.92 M |
| 09/30/2024 | Q3 2024 | N/A | -$1.69 | N/A | $70.09 M | $57.83 M |
| 06/29/2024 | Q2 2024 | N/A | -$1.91 | N/A | $82.80 M | $36.00 M |
| 05/02/2024 | Q1 2024 | -$1.62 | -$2.30 | -0.68 | $79.81 M | $95.89 M |
| 02/07/2024 | Q4 2023 | -$2.19 | -$1.53 | 0.66 | $93.73 M | $137.70 M |
| 09/29/2023 | Q3 2023 | N/A | -$2.88 | N/A | $49.05 M | $48.03 M |
| 06/30/2023 | Q2 2023 | N/A | -$2.16 | N/A | $37.24 M | $47.39 M |
| 04/27/2023 | Q1 2023 | -$2.93 | -$1.98 | 0.95 | $21.50 M | $33.59 M |
| 02/16/2023 | Q4 2022 | -$2.74 | -$3.70 | -0.96 | $19.15 M | $22.90 M |
| 09/30/2022 | Q3 2022 | N/A | -$3.03 | N/A | $8.81 M | $15.29 M |
| 06/30/2022 | Q2 2022 | N/A | -$1.46 | N/A | $5.60 M | $6.16 M |
| 05/11/2022 | Q1 2022 | -$2.09 | -$2.21 | -0.12 | $4.55 M | $6.83 M |
| 03/02/2022 | Q4 2021 | -$2.57 | -$1.97 | 0.6 | $2.71 M | $4.90 M |
| 11/10/2021 | Q3 2021 | -$2.63 | -$1.47 | 1.16 | $1.14 M | $1.11 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Ascendis Pharma A/S Earnings: FAQ's
In the previous quarter, Ascendis Pharma A/S (:ASND) reported $3.29 earnings per share (EPS) to beat the analysts' consensus estimate of $1.71 by $1.58.
The conference call for Ascendis Pharma A/S's latest earnings report can be listened to online.
The conference call transcript for Ascendis Pharma A/S's latest earnings report can be read online.
Ascendis Pharma A/S (:ASND) has a recorded annual revenue of $691.71 M.
Ascendis Pharma A/S (:ASND) has a recorded net income of $-219,034,140.Ascendis Pharma A/S has generated $-3.62 earnings per share over the last four quarters.
Ascendis Pharma A/S (:ASND) has a price-to-earnings ratio of 17.94 and price/earnings-to-growth ratio is 0.03.